The inhibition of mTOR enhances the sensitivity of a broad range of chemocytotoxic agents, including cisplatin, carboplatin, doxorubicin, mitoxantrone and doxcetaxel in numerous types of human cancers. This evidence concerns the gene MTOR and cancer.